Genomic Valley Biotech Ltd
Incorporated in 2001, Genomic Valley Biotech Ltd is in the business of Horticultural and Agricultural products, and is also adding activities in Human Genomic[1]
- Market Cap ₹ 9.22 Cr.
- Current Price ₹ 30.2
- High / Low ₹ 41.0 / 20.1
- Stock P/E 922
- Book Value ₹ 12.8
- Dividend Yield 0.00 %
- ROCE 1.02 %
- ROE 0.77 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 5.15% over past five years.
- Company has a low return on equity of 3.68% over last 3 years.
- Company has high debtors of 3,136 days.
- Promoter holding has decreased over last 3 years: -21.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.84 | 0.27 | 0.22 | |
| 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.30 | 0.34 | 0.45 | 1.84 | 0.15 | 0.40 | 0.23 | 0.19 | |
| Operating Profit | -0.04 | -0.43 | -0.04 | 0.10 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.44 | 0.04 | 0.03 |
| OPM % | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 52.38% | 14.81% | 13.64% |
| 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | -0.22 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.20 | -0.50 | 0.00 | 0.65 | 0.02 | 0.44 | 0.04 | 0.03 |
| Tax % | 0.00% | -2.94% | 0.00% | 40.00% | 0.00% | -40.00% | 12.00% | 0.00% | 0.00% | 20.45% | 25.00% | ||
| -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.36 | 0.03 | 0.01 | |
| EPS in Rs | -0.03 | -1.08 | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.18 | 0.10 | 0.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 5% |
| 3 Years: | -54% |
| TTM: | -72% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 15% |
| 3 Years: | -68% |
| TTM: | -96% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 6% |
| 3 Years: | 9% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 5% |
| 3 Years: | 4% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 1.84 | 1.51 | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.84 | 0.87 |
| 0.75 | 0.75 | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.80 | 0.73 | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.90 | 0.79 | 0.47 | 0.33 | |
| Total Liabilities | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.25 |
| 3.15 | 3.18 | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | 0.00 | 0.00 | 0.01 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.38 | 0.49 | 0.49 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.55 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| 2.74 | 2.75 | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.35 | 4.25 | |
| Total Assets | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.36 | 4.25 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.09 | -0.69 | 0.35 | 0.87 | -1.04 | 0.44 | 1.48 | -2.13 | -0.78 | -0.02 | 0.03 | -0.02 | |
| -0.65 | 0.53 | -0.31 | -0.91 | 0.37 | -0.47 | -1.58 | 3.67 | 1.52 | -0.02 | 0.01 | 0.00 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.73 | 0.00 | 0.07 | -1.55 | -0.70 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | -0.56 | -0.16 | 0.04 | -0.04 | 0.06 | -0.04 | -0.03 | -0.01 | 0.04 | -0.04 | 0.04 | -0.02 |
| Free Cash Flow | -0.05 | -0.77 | -0.15 | -0.07 | -0.68 | -0.04 | -0.10 | 3.22 | 0.70 | -0.02 | 0.02 | -0.02 |
| CFO/OP | -225% | 160% | -875% | 870% | -248% | 80% | -1,138% | 561% | -89% | -100% | 27% | -25% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 960.30 | 3,136.30 |
| Inventory Days | 0.00 | 0.00 | 0.00 | 0.00 | 486.67 | |||||||
| Days Payable | 17.38 | |||||||||||
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 12.37 | 22.12 | 42.94 | 104.29 | 0.00 | 297.90 | 5,432.06 | 1,429.58 | 3,136.30 |
| Working Capital Days | -8,881.67 | -1,659.09 | -514.32 | -804.24 | 55.30 | -176.06 | -1,251.43 | 4,849.29 | 221.42 | 4,530.29 | 916.85 | 3,176.85 |
| ROCE % | 0.35% | -5.84% | -0.57% | 0.57% | 4.17% | 5.96% | -5.10% | -8.54% | 28.48% | 0.57% | 11.84% | 1.02% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Audit Committee Meetings Held count |
|
|||||
| Number of Board Meetings Held count |
||||||
| Number of Directors on Board count |
||||||
| Number of Present Activities (Business Lines) count |
||||||
| Number of Crop Varieties Cultivated/Traded count |
||||||
| Number of Farmers in Farmers Producer Company (FPC) count |
||||||
| Number of Permanent Employees count |
||||||
| Total Number of Shareholders count |
||||||
Extracted by Screener AI
Documents
Announcements
-
Intimation Of Approval Of Extension Of Time For Holding Annual General Meeting (AGM) Of The Company For The Financial Year Ended On 31St March 2026, Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015
- ROC Haryana granted Genomic Valley Biotech a 3-month AGM extension until 31 December 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Unaudited financial results for the quarter ended on 30th June, 2026.
-
Results-Financial Results For Quarter Ended On 30 June 2026.
- Board approved standalone unaudited Q1 FY2027 results on 14 August 2026.
-
Board Meeting Outcome for Outcome Of The Board Meeting Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015 Held On Today I.E. 14Th August 2026
- Board approved standalone unaudited results for quarter ended 30 June 2026.
-
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone) Of The Company For The Quarter Ended On June 30, 2026
- Board meets August 14, 2026 to approve Q1 FY2026-27 standalone results; trading window closed until 48 hours after results.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Business Overview:[1][2]
GVBL, with its experience in Next-Generation Sequencing (NGS), oncology, and Artificial Intelligence (AI), provides biotechnology
and healthcare solutions. The company provides personalized therapy options, helping doctors with decision-making support and identifying effective treatments, and aims to transform oncology research and diagnostics.
The company also provides Research Process Outsourcing (RPO) services to global researchers